title: Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.
abstract: Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver diseases, including cirrhosis and hepatocellular carcinoma, because we are unable to eliminate chronic HBV infection. Available therapies for chronic HBV infection mainly include nucleos/tide analogues (NAs), non-NAs, and immunomodulatory agents. However, none of them is able to clear chronic HBV infection. Thus, a new generation of anti-HBV drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection. This review aims to summarize the state of the art in new HBV drug research and development and to forecast research and development trends and directions in the near future.
authors.affiliation: Department of Clinical Pharmacy, Shanghai First People's Hospital, Shanghai Jiao Tong University, 650 New Songjiang Road, Songjiang District, Shanghai 201620, China. lakekang@163.com.
authors.forename: Lei
authors.initials: L
authors.lastname: Kang
authors.affiliation: Department of Clinical Pharmacy, Shanghai First People's Hospital, Shanghai Jiao Tong University, 650 New Songjiang Road, Songjiang District, Shanghai 201620, China. pan_jiaqian@163.com.
authors.forename: Jiaqian
authors.initials: J
authors.lastname: Pan
authors.affiliation: Department of Pharmacy, Ningbo Medical Treatment Center Lihuili Hospital, 57 Xingning Road, Ningbo 315040, China. xjtuwjf@163.com.
authors.forename: Jiaofen
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Pharmacy, The Third Staff Hospital of Baogang Group, 15 Qingnian Road, Baotou 014010, China. hujiali1989@126.com.
authors.forename: Jiali
authors.initials: J
authors.lastname: Hu
authors.affiliation: Department of Clinical Pharmacy, Shanghai First People's Hospital, Shanghai Jiao Tong University, 650 New Songjiang Road, Songjiang District, Shanghai 201620, China. sq15895820107@126.com.
authors.forename: Qian
authors.initials: Q
authors.lastname: Sun
authors.affiliation: Department of Clinical Pharmacy, Shanghai First People's Hospital, Shanghai Jiao Tong University, 650 New Songjiang Road, Songjiang District, Shanghai 201620, China. angel_tj99@126.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Tang
mesh_terms: D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology* / Q000627:therapeutic use; D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends; D006515:Hepatitis B virus / Q000187:drug effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D000998:Antiviral Agents
keywords: anti-HBV drugs; guidelines; hepatitis B virus; research and development